Search details
1.
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Lancet Oncol
; 18(9): 1261-1273, 2017 09.
Article
in English
| MEDLINE | ID: mdl-28729154
Results
1 -
1
de 1
1
Next >
>>